

JPET # 262733

Mice with *GNAO1* R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone

Authors: Larrivee, Casandra L.^{1,2,} Feng, Huijie², Quinn, Josiah A.², Shaw, Vincent,
S.², Leipprandt, Jeffrey R.², Demireva, Elena Y.³, Xie, Huirong³, and Neubig,
Richard R.^{2,4*}

¹ Department of Comparative Medicine and Integrative Biology,

Michigan State University

784 Wilson Rd, East Lansing MI, 48824 US

²Department of Pharmacology & Toxicology,

Michigan State University

1355 Bogue Street, East Lansing, MI 48824 US

³ Transgenic and Genome Editing Facility

Institute for Quantitative Health Science and Engineering

Michigan State University

775 Woodlot Drive, East Lansing MI 48823 US

⁴ Nicholas V. Perricone, M.D., Division of Dermatology

Department of Medicine

Michigan State University

1355 Bogue Street

East Lansing, MI 48824

JPET # 262733

Running Title: Movement phenotype in *Gnao1* R209H mutant mice

Richard. R. Neubig, M.D., Ph.D.

*Corresponding Author

Tel: 001-517-353-7145

Fax: 517-353-8915

E-mail address: rneubig@msu.edu

Mailing address: 1355 Bogue Street B440, Life Science Building, East Lansing, MI,
48824, US

The number of text pages: 21

number of tables: 1

number of figures: 6

number of references: 45

number of words in the *Abstract*: 241

number of words in the *Introduction*: 739

number of words in the *Discussion*: 939

Section Recommendation: Behavioral Pharmacology

JPET # 262733

Abbreviations

AC: Adenylyl Cyclase

cAMP: Cyclic adenosine monophosphate

EIEE17: Early infantile epileptic encephalopathy 17

GOF: Gain-of-function

GPCR: G-protein coupled receptor

GTP γ S: 5'-Guanosine-diphosphate-monothiophosphate

LOF: Loss-of-function

NEDIM: Neurodevelopmental disorder with involuntary movements

RNP: Ribonucleoprotein

tracrRNA: Trans-activating crRNA

crRNA: CRISPR RNA

ssODN: Single-stranded oligodeoxynucleotide

DSB: Double strand DNA break

PAM: Protospacer-adjacent motif

JPET # 262733

Abstract

Neurodevelopmental disorder with involuntary movements (NEDIM, OMIM: 617493) is a severe, early onset neurological condition characterized by a delay in psychomotor development, hypotonia, and hyperkinetic involuntary movements. Heterozygous *de novo* mutations in the *GNAO1* gene cause NEDIM. $G\alpha_o$, the gene product of *GNAO1*, is the alpha subunit of G_o , a member of the heterotrimeric $G_{i/o}$ family of G-proteins. G_o is found abundantly throughout the brain but the pathophysiological mechanisms linking $G\alpha_o$ functions to clinical manifestations of *GNAO1*-related disorders are still poorly understood. One of the most common mutant alleles among the *GNAO1* encephalopathies is the c.626G>A or p.Arg209His (R209H) mutation. We developed heterozygous knock-in *Gnao1*^{+/R209H} mutant mice using CRISPR/Cas9 methodology to assess whether a mouse model could replicate aspects of the NEDIM clinical pattern. Mice carrying the R209H mutation exhibited increased locomotor activity and a modest gait abnormality at 8-12 weeks. In contrast to mice carrying other mutations in *Gnao1*, the *Gnao1*^{+/R209H} mice did not show enhanced seizure susceptibility. Levels of protein expression in multiple brain regions were unchanged from WT mice but the nucleotide exchange rate of mutant R209H $G\alpha_o$ was 6.2x faster than WT. The atypical neuroleptic risperidone has shown efficacy in a patient with the R209H mutation. It also alleviated the hyperlocomotion phenotype observed in our mouse model but suppressed locomotion in WT mice as well. In this study, we show that *Gnao1*^{+/R209H} mice mirror elements of the patient phenotype and respond to an approved pharmacological agent.

JPET # 262733

Significance Statement:

Children with *de novo* mutations in the *GNAO1* gene may present with movement disorders with limited effective therapeutic options. The most common mutant variant seen in children with *GNAO1*-associated movement disorder is R209H. Here we show, using a novel *Gnao1*^{+/*R209H*} mouse, that there is a clear behavioral phenotype that is suppressed by risperidone. However, risperidone also affects WT mouse activity, so its effects are not selective for the *GNAO1*-associated movement disorder.

Introduction

$G\alpha_o$ is the alpha subunit of the heterotrimeric G protein G_o . It is the most abundant heterotrimeric G protein in the central nervous system comprising 1% of mammalian brain membrane protein. Mutations in *GNAO1*, which encodes $G\alpha_o$, have been linked to two distinct neurological conditions. In 2013, four children with early infantile epileptic encephalopathy were identified with mutations in *GNAO1* (Nakamura et al., 2013). Since then, a growing number of patients presenting with epilepsy and/or hyperkinetic movement disorders have been found to exhibit *de novo* mutations in *GNAO1* (Feng et al., 2017; Feng et al., 2018). It was recognized in 2016 that some *GNAO1* mutations result in movement disorders without epilepsy (Kulkarni et al., 2016; Saitsu et al., 2016). To date there are over 70 published cases of children with mutations in *GNAO1* presenting with early infantile epileptic encephalopathy (EIEE17: OMIM 615473) and/or neurodevelopmental disorder with involuntary movements (NEDIM: OMIM 617493) (Nakamura et al., 2013; Consortium et al., 2014; Law et al., 2015; Talvik et al., 2015; Ananth et al., 2016; Consortium, 2016; Dhamija et al., 2016; Gawlinski et al., 2016; Kulkarni et al., 2016; Marcé-Grau et al., 2016; Menke et al., 2016; Saitsu et al., 2016; Sanem et al., 2016; Arya et al., 2017; Danti et al., 2017; Sakamoto et al., 2017; Schorling et al., 2017; Blumkin et al., 2018; Bruun, 2018; Gerald et al., 2018; Honey et al., 2018; Koy et al., 2018; Marecos et al., 2018; Okumura et al., 2018; Rim et al., 2018; Schirinzi et al., 2018; Takezawa et al., 2018; Waak et al., 2018; Xiong et al., 2018; Meredith et al., 2019).

JPET # 262733

More than forty pathological variants of *GNAO1* have been reported. Using a cell-based biochemical signaling assay, we classified many of those $G\alpha_o$ variants for their ability to inhibit cAMP production in transfected HEK293 cells (Feng et al., 2017). Some mutant $G\alpha_o$ proteins were unable to support receptor-mediated inhibition of cAMP which classifies them as having a loss-of-function (LOF) mechanism *in vitro*. These LOF mutants were associated with epilepsy (Feng et al., 2017). In contrast, mutations resulting in enhanced cAMP inhibition (gain-of-function, GOF) or normal cAMP regulation (NF) were generally associated with movement disorders. (Feng et al., 2017).

To permit mechanistic studies and preclinical drug testing, we had previously created a mouse model with a *GNAO1* GOF mutation, G203R, that was identified in patients who showed both epilepsy and movement disorders (Saito et al., 2016). As predicted, the *Gnao1*^{+/G203R} (G203R) mutant mice exhibited motor coordination and gait abnormalities as well as enhanced seizure susceptibility in pentylenetetrazol (PTZ) kindling studies (Feng et al., 2019). The R209H mutation is one of the most common pathogenic *GNAO1* mutations (Schirinzi et al., 2018). Patients with *de novo*, heterozygous R209H mutations in *GNAO1* display severe choreoathetosis and dystonia but do not exhibit seizures (Supplemental Table 1). Interestingly, the R209H mutation was found to have essentially normal function for cAMP inhibition in HEK 293T cells. Despite this normal function in an *in vitro* assay, it causes a severe form of movement disorder in patients, often requiring intensive care unit admission (Ananth et al., 2016; Marecos et al., 2018). This discrepancy between the normal functionality *in vitro* and its clear clinical pathologic role made the R209H mutation of substantial interest for *in vivo* physiological studies.

JPET # 262733

We used a battery of behavioral tests to measure motor skills in heterozygous *Gnao1*^{+/_{R209H}} mutant mice as well as PTZ kindling studies to assess seizure susceptibility. As expected *Gnao1*^{+/_{R209H}} mice did not show enhanced seizure susceptibility in PTZ kindling studies. Male and female *Gnao1*^{+/_{R209H}} mice displayed significant hyperactivity in an open field assessment. This finding was surprising as mice in our previous *GNAO1*-related movement disorder model, *Gnao1*^{+/_{G203R}} did not show significant differences on the open field test (Feng et al., 2019). This difference in movement phenotype is consistent with the wide heterogeneity of movement patterns displayed by patients with *GNAO1* mutations (Nakamura et al., 2013; Ananth et al., 2016; Dhamija et al., 2016; Kulkarni et al., 2016; Marcé-Grau et al., 2016; Menke et al., 2016; Feng et al., 2018).

Having a mouse model with a strong movement phenotype allowed us to begin allele-specific preclinical drug testing and will facilitate mechanistic studies of *GNAO1* mutants. The neuroleptic risperidone was reportedly beneficial in a patient a *GNAO1* R209H mutation (Ananth et al., 2016). Here we show risperidone attenuates hyperactivity in our R209H mutant mice. This suggests risperidone or related agents may be beneficial for *GNAO1* patients with the R209H mutation.

Materials and Methods

Animals

Gnao1^{+/*R209H*} mice on a C57BL/6J background were generated in the MSU Transgenic and Gene Editing Facility (<https://tgef.vprgs.msu.edu>) as described below. Mice (8-12 weeks old) were housed on a 12-hour light/dark cycle, with *ad libitum* access to food and water. All experiments were performed in accordance with NIH guidelines and protocols approved by the Michigan State University Institutional Animal Care and Use Committee.

Generation of Gnao1 R209H edited mice

Mutant *Gnao1*^{+/*R209H*} mice were generated via CRISPR/Cas9 genome editing on a C57BL/6J genomic background. CRISPR gRNA selection and locus analysis were performed using the Benchling platform (Benchling, Inc. San Francisco, CA.). A gRNA targeting exon 6 of the *Gnao1* locus (ENSMUSG00000031748) was chosen to cause a double strand break (DSB) 3bp downstream of codon R209. A single stranded oligodeoxynucleotide (ssODN) carrying the R209H mutation CGC > CAC with short homology arms was used as a repair template (Figure 1 and Table 1). Ribonucleoprotein (RNP) complexes consisting of a synthetic crRNA/tracrRNA hybrid and Alt-R® S.p. Cas9 Nuclease V3 protein (Integrated DNA Technologies, Inc. Coralville, IA), were used to deliver CRISPR components along with the ssODN to mouse zygotes via electroporation as previously described (Feng et al., 2017; Feng et al., 2019). Edited embryos were implanted into pseudo-pregnant dams using standard techniques. Resulting litters were

JPET # 262733

screened by PCR (Phire Green HSII PCR Mastermix, F126L, Thermo Fisher, Waltham, MA.), T7 Endonuclease I assay (M0302, New England Biolabs Inc.) and Sanger sequencing (GENEWIZ, Inc. Plainfield, NJ) for edits of the target site.

Genotyping and Breeding

Studies were done on N1 R209H heterozygotes with comparisons to littermate controls. To generate *Gnao1^{+/R209H}* heterozygotes (N1 backcross), 2 founder *Gnao1^{+/R209H}* mice, 1 male and 1 female, were crossed with WT C57BL/6J mice obtained directly from The Jackson Laboratory (Bar Harbor, ME).

DNA was extracted by an alkaline method (26) from ear clips done before weaning. PCR products were generated with primers flanking the mutation site (Fwd 5' GGACAGGTGTCACAGGGGAT 3'; 5' ACTGGCCTCCCTTGGCAATA 3') which produces a 375 base pair (bp) product. Reaction conditions were: 0.8 µl template, 4 µl 5x Promega PCR buffer, 0.4 µl 10mM dNTPs, 1 µl 10 µ M Forward Primer, 1 µl 10 µ M Reverse Primer, 0.2 µl Promega GoTaq and 12.6 µl DNase free water (Promega catalog # M3005, Madison WI). Samples were denatured for 4 minutes at 95 °C then underwent 32 cycles of PCR (95 °C for 30 seconds, 63 °C for 30 seconds, and 72 °C for 30 seconds) followed by a 7 minute final extension at 72 °C. Ethanol precipitation was done on the PCR products and then samples were sent for Sanger sequencing (GENEWIZ, Inc. Plainfield, NJ).

Behavioral Assessment

Male and female *Gnao1^{+/-R209H}* mice (8-12 weeks of age) and their *Gnao1^{+/+}* littermates underwent a battery of behavioral testing to assess motor phenotype as described previously (Feng et al., 2019). Before each experiment, mice were acclimated for 10 minutes to the testing room. Experiments were performed by two female researchers. All behavioral studies were done by individuals who were blind to the genotype of the animals until completion of data collection.

Open Field

The open field test is frequently used to assess locomotion, exploration and anxiety (Tatem et al., 2014; Seibenhener and Wooten, 2015; Feng et al., 2019). The test was conducted in Fusion VersaMax clear 42 cm x 42cm x 30cm arenas (Omnitech Electronics, Inc., Columbus, Ohio). *Gnao1^{+/-R209H}* mice of both sexes and their littermates were placed in the arena for 30 minutes. Using the Fusion Software, we evaluated distance traveled (cm) in terms of novelty, sustained, and total movement corresponding to the first 10 minutes, 10-20 minutes, and total of 30 minutes. As a potential measure of anxiety, the fraction of time spent in the center was assessed. The center area was defined as the 20.32cm x 20.32cm area within the middle of the arena.

Rotarod

To assess motor skills, we used the Economex accelerating RotaRod (Columbus Instruments, Columbus OH). The protocol occurred over a two-day period. On day 1, mice were trained for three 2-min training sessions, with 10 minutes between each

JPET # 262733

training trial. During the first two sessions, the rotarod maintained a constant rotational speed of 5 rpm. The third training trial started at 5 rpm and accelerated at 0.1 rpm/sec for 2 minutes. The following day, mice ran three more trials with a 10-min break in between: two more 2-min training trials and a final 5-min test trial. Each of these trials started at 5 rpm with constant acceleration of 0.1 rpm/sec. For all training and test trials, latency to fall off the spindle was recorded in seconds.

Grip Strength

To assess mouse grip strength, we used seven home-made weights (10, 18, 26, 34, 42, 49, 57 grams) with a 2.54 cm ring for the mouse to grasp. The mouse was held by the middle/base of the tail and lowered to the weight. Once the mouse grasped the weighted ring with its forepaws, the mouse was lifted until the weight cleared the bench. For each weight, the mouse was given up to three trials to suspend the weight above the table for 3 seconds. If cleared, the next heaviest weight was tried. If the weight wasn't held, the total time and maximum weight lifted was recorded and a grip strength score calculated from (Deacon et al., 2016). The calculated score was normalized to mouse body weight which was measured the day of the test.

DigiGait

Mouse gait analysis was performed on a DigiGait apparatus (Mouse Specifics, Inc, Framingham, MA). After acclimation, each mouse was placed on the treadmill at speeds of 18, 20, 22, 25, 28, 32, 36 cm/s. A 10-second clip was recorded with a video camera located below the belt. There was a 5-min rest between each speed. Recordings were

JPET # 262733

analyzed with the DigiGait analysis program to assess the pre-specified parameters of stride length and paw angle variability. Values for all four paws were averaged to give one value per mouse – the reported n values are the number of mice. In addition, the maximum speed at which each mouse was able to successfully complete a 10-second test after three attempts was recorded as described (Feng et al., 2019).

PTZ Kindling Study

A PTZ kindling protocol was performed as described (Kehrl et al., 2014; Feng et al., 2019) to assess mouse susceptibility to seizure induction. Mice were injected with a sub-convulsive dose of PTZ (40 mg/kg, i.p.) every other day for up to 24 days mice then were observed for 30 minutes post-dose. Kindling was defined as death or tonic-clonic seizures on two consecutive injection days after which mice were euthanized. Kaplan-Meier survival analysis was done based on the number of injections to achieve kindling.

Gα_o protein expression

Mice (6-8 weeks old) were sacrificed and their brains were dissected into different regions and flash-frozen in liquid nitrogen. For Western Blot analysis, tissues were thawed on ice and homogenized for 5 min with 0.5 mm zirconium beads in a Bullet Blender (Next Advance; Troy, NY) in RIPA buffer (20mM Tris-HCl, pH7.4, 150mM NaCl, 1mM EDTA, 1mM β-glycerophosphate, 1% Triton X-100 and 0.1% SDS) with protease inhibitor (Roche/1 tablet in 10 mL RIPA). Sample homogenates were centrifuged for 5 min at 4°C at 13,000 G. Supernatants were collected and protein concentrations determined using the bicinchoninic acid method (BCA method; Pierce; Rockford, IL).

JPET # 262733

Protein concentration was normalized for all tissues with RIPA buffer and 2x SDS sample buffer containing β -mercaptoethanol (Sigma-Aldrich) was added. Thirty μ g of protein was loaded onto a 12% Bis-Tris SDS-PAGE gel and samples were separated for 1.5 hrs at 160V. Proteins were then transferred to an Immobilon-FL PVDF membrane (Millipore, Billerica, MA) on ice either for 2 h at 100 V, 400 mA or overnight at 30V, 50mA. Immediately after transfer, PDVF membranes were washed and blocked in Odyssey PBS blocking buffer (Li-Cor) for 40 min at RT. The membranes were then incubated with anti-G α o (rabbit; 1:1,000; sc-387; Santa Cruz biotechnologies, Santa Cruz, CA) and anti-actin (goat; 1:1,000; sc-1615; Santa Cruz) antibodies diluted in Odyssey blocking buffer with 0.1% Tween-20 overnight at 4°C. Following four 5-min washes in phosphate-buffered saline with 0.1 % Tween-20 (PBS-T), the membrane was incubated for 1 hr at room temperature with secondary antibodies (both 1:10,000; IRDye® 800CW Donkey anti-rabbit; IRDye® 680RD Donkey anti-goat; LI-COR Biosciences) diluted in Odyssey blocking buffer with 0.1 % Tween-20. The membrane was subjected to four 5-min washes in PBS-T and a final rinse in PBS for 5 min. The membrane was kept in the dark and the infrared signals at 680 and 800nm were detected with an Odyssey Fc image system (LI-COR Biosciences). The G α o polyclonal antibody recognizes an epitope located between positions 90-140 G α o (Santa Cruz, personal communication) so there should be no interference from the R209H mutation.

Kinetics of nucleotide binding

To estimate GDP release rates, which can control activation of G proteins, we measured the kinetics of binding of the fluorescent ligand BODIPY FL GTP γ S as

JPET # 262733

described previously (McEwen et al., 2002). In brief, WT and mutant his6-tagged Gα_o subunits were expressed in E coli and purified by Ni-NTA affinity chromatography as previously described (Lee et al., 1994) and stored frozen at -80 C in 50 mM HEPES 100 mM NaCl buffer containing 50 uM GDP to stabilize the protein. Protein was diluted to 200 nM in binding buffer (50 mM HEPES, 10 mM MgCl₂, 1 mM EDTA and 1 mM DTT, pH 8.0) then 100 nM BODIPY-GTP_γS was added and fluorescence monitored at 485 nm ex, 510 nm em in a Tecan Infinite M1000 Pro microplate reader at 24 °C. Experiments were done on three different days each in duplicate and results averaged. Rate constants and t_{1/2} were determined by fitting results to the equation $Y = Y_0 + (Y_{max} - Y_0) * (1 - e^{-k * t})$ in GraphPad Prism v. 8 where Y₀ was constrained to be shared between the WT and R209H mutant data sets.

Risperidone effects on motor behavior

Naïve 8-12 week old *Gnao1*^{+/-R209H} and *Gnao1*^{+/+} littermates of either sex were tested for effects of risperidone on their activity in the open field arena. The study was run over 5 days: On day 1, mice underwent the open field protocol described above to establish a baseline. On day 3, mice were habituated in the experimental room for 10 min then given a single i.p. dose of 2.0 mg/kg risperidone (Cayman Chemical, Ann Arbor, MI) or vehicle control. Risperidone was dissolved in DMSO at a concentration of 5 mg/ml, Further dilutions were done in DI water. Thirty minutes following injection, mice were placed in the open field arena for a 30-minute testing time. On day 5, mice were retested in the same open field protocol without injection to assess drug washout. A week later the

JPET # 262733

same protocol was followed to test the effects an i.p. dose of 0.5 mg/kg risperidone had on the WT and R209H mice.

Statistical Analysis

Data were analyzed with unpaired Student's *t*-test or Mantel-Cox, *two-way* ANOVA with Bonferroni corrections as appropriate using Graphpad Prism 7.0 (GraphPad; La Jolla, CA). A $p < 0.05$ was considered the cut off for significance throughout. Detailed discussion of statistical analyses can be found within figure legends.

Results

Gnao1^{+/-R209H} mice are produced at the expected frequency and have normal viability

Two founder *Gnao1^{+/-R209H}* mice, 1 male and 1 female, were crossed with C57BL/6J mice. Out of 98 offspring of a cross of *Gnao1^{+/-R209H}* with WT mice, 51 heterozygotes and 47 WT were observed. *Gnao1^{+/-R209H}* mice exhibit no overt postural or movement abnormalities or seizures under normal housing conditions. Adult mice showed no statistically significant differences in weight between WT and *Gnao1^{+/-R209H}* genotypes of either sex.

Both male and female Gnao1^{+/-R209H} show significant hyperactivity in the open field arena but no significant differences on the rotarod or grip strength test

Patients with R209H mutations present with hyperkinetic movement disorders (Ananth et al., 2016; Dhamija et al., 2016; Menke et al., 2016). To detect motor abnormalities, *Gnao1^{+/-R209H}* mice were subjected to a battery of behavioral tests. The open field arena was used to test overall locomotor activity. We divided the test into two sections reflecting activity in a novel environment (0-10 minutes) then sustained activity (10-30 min). *Gnao1^{+/-R209H}* mice of both sexes showed markedly increased activity in the sustained activity period compared to their wildtype littermates (Figure 2B). Females also had significantly increased activity in the first 10 minutes (novelty period, Fig. 2B). As a potential indicator of anxiety-like behavior. Male and female *Gnao1^{+/-R209H}* mice also displayed reduced time in center (Figure 2A and 2B).

JPET # 262733

An accelerating rotarod test was used to assess motor coordination and balance. Neither male nor female *Gnao1^{+/-R209H}* mice display impaired performance (Figure 2C). Also grip strength, showed no differences between *Gnao1^{+/-R209H}* and wildtype littermates of either sex (Figure 2D).

Male Gnao1^{+/-R209H} mice display a modestly reduced stride length

Gait patterns were assessed using DigiGait analysis. Male *Gnao1^{+/-R209H}* mice showed a highly significant genotype effect with reduced stride length compared to wildtype littermates ($P < 0.001$, 2-way ANOVA) but the magnitude of the effect was modest (5.6% decrease averaged across all speeds). In post-test analysis, only the top speed (36 cm/sec) reached significance individually ($p < 0.01$). Female *Gnao1^{+/-R209H}* mice did not show significant differences in stride length from WT (Figure 3C & 3D). However as previously reported for G203R mutant mice, the female *Gnao1^{+/-R209H}* showed a significantly reduced maximum run speed on the treadmill (Figure 3E $p < 0.01$, t-test). This was not due to reduced body size as length, as detected by the digigait system, (WT 9.54 cm: vs R209H 10.17 cm), and weights were not significantly different. There was no significant difference in paw angle variability for either males or females. All parameters of DigiGait analysis are shown in supplemental table 3 & 4 and false discovery rate (FDR) calculation probed of significantly different parameters from the DigiGait data in *Gnao1^{+/-R209H}* mice is shown in supplemental figure 2.

Gnao1^{+/-R209H} mice are not sensitive to PTZ kindling

Repeated application of a sub-threshold convulsive stimulus leads to the generation of full-blown convulsions in a process called kindling (Dhir, 2012). *GNAO1* variants differ in their ability to cause epileptic seizures in patients. Those carrying the R209H mutant allele do not exhibit a seizure disorder (Ananth et al., 2016; Kulkarni et al., 2016; Menke et al., 2016). In accordance with the patients' pattern, *Gnao1^{+/-R209H}* mice did not show increased susceptibility to kindling-induced seizures (Figure 4A & 4B). This contrasts with our previous report of increased kindling sensitivity in male G203R and female G184S mutant mice (Kehrl et al., 2014; Dhamija et al., 2016; Feng et al., 2019).

Gnao1^{+/-R209H} mice have normal Gα_o protein expression in the brain

To understand why R209H mutant mice do not show a phenotypic difference in the kindling test while G203R mutants do, we assessed Gα_o protein expression levels. Cortex, hippocampus, striatum, cerebellum, brain stem and olfactory bulb were harvested and homogenized to measure the effect of the R209H mutation on Gα_o protein expression. Western blots showed no difference in Gα_o protein expression between WT and *Gnao1^{+/-R209H}* mice in any of the measured brain regions (Figure 5A & 5B). This is consistent with our previous analysis of protein expression in HEK293T cells with transiently transfected Gα_o R209H plasmid (Feng et al., 2017). The normal expression of the R209H mutant contrasts with the reduced expression of Gα_o in brains of Gα_o ^{+/G203R} mutant mice (Feng et al., 2019).

Kinetics of nucleotide binding to mutant G α _o

Both patients and mice heterozygous for the G α _o R209H mutation display movement phenotypes however, the mutant G α _o supports normal cAMP regulation in the cell-based cAMP assay (Feng et al., 2017). To consider possible mechanisms for this discrepancy we measured the rate of GDP release from mutant G α _o using the BODIPY-GTP γ S binding kinetics method (McEwen et al., 2002). The rate of GTP γ S binding to WT G α _o was slow ($T_{1/2}$ 1261 seconds, Fig. 5C) as expected. The R209H mutant G α _o showed markedly faster binding of BODIPY-GTP γ S ($T_{1/2}$ 203 seconds 6.2x faster than WT, Fig. 5C & D) suggesting a faster rate of GDP release. In addition to the faster rate of binding, the amplitude of binding was lower for the R209H mutant. While this lower amplitude of binding might be due to either a lower affinity of the mutant for the BODIPY-GTP γ S or to instability under the binding conditions we do show that the R209H mutant definitely does have abnormal interactions with nucleotides – GDP and/or GTP.

Risperidone treatment attenuated the hyperactivity of Gnao1^{+/-}R209H mice

Patients with *GNAO1* mutations were tried on multiple drugs to alleviate motor symptoms (Table S1). Risperidone, an atypical antipsychotic drug showed beneficial effects in one of the patients. It has also been effective in drug-induced dyskinesia (Carvalho et al., 2003). We show that *Gnao1^{+/-}R209H* mice exhibit complete abrogation of movement at 2 mg/kg risperidone, which recovered upon retesting 2 days later (Figure 6A&C). WT mice also show a significant decrease in locomotion after 2 mg/kg risperidone treatment (Figure 6A). After a single 0.5 mg/kg dose of risperidone both WT and

JPET # 262733

Gnao1^{+/*R209H*} mice exhibit a decrease in locomotion compared to vehicle treated littermates (Figure 6B). As expected, hyperactivity of mutant mice was observed during baseline testing on day 1 and the hyperactivity had returned on day 5 following the 2-day washout period after the risperidone doses (Figure 7C). Neither 2.0 mg/kg nor 0.5 mg/kg selectively affected *Gnao1*^{+/*R209H*} as assessed by percent suppression of distance travelled (Supplemental Figure 1).

Discussion

We have developed a novel mouse model carrying an R209H mutation in the *Gnao1* gene that leads to a serious movement disorder (Ananth et al., 2016; Dhamija et al., 2016). While *GNAO1* mutations are rare in humans, the R209H mutation is the second most common found in patients with *GNAO1*-related disorders. The mice have a clear movement phenotype confirming the pathological nature of this mutation despite earlier work showing that it could normally support receptor-mediated regulation of cAMP in HEK cells (Feng et al., 2017). This model will provide a powerful tool to both understand neural mechanisms of the dysfunction of the R209H $G\alpha_o$ protein as well as permitting preclinical drug repurposing studies.

The goal of personalized medicine is to define treatments for an individual patient. Knowing which gene is involved is beneficial but different mutant alleles, even in the same gene, can produce quite distinct effects. Here we report a second mouse model of *GNAO1*-related neurological abnormalities. The *Gnao1* R209H mutant mice display motor abnormalities but no seizures which differs from our previous *Gnao1* G203R mouse model (Feng et al., 2019). This is consistent with the clinical pattern of *GNAO1* R209H patients, who present with neurodevelopmental delay with involuntary movements (NEDIM) without seizures (Ananth et al., 2016; Dhamija et al., 2016).

The specific movement abnormalities seen with the *Gnao1* R209H mutant mice were somewhat unexpected; our previous mouse model, *Gnao1*^{+G203R}, showed significant motor impairments in Rotarod and Digigait but had no changes in the open field test (Feng et al., 2019). In contrast, the *Gnao1* R209H mutant mice reported here have profound hyperactivity in the open field test and either no or only modest deficits in

JPET # 262733

rotarod and digigait analysis. Patients with the G203R or R209H mutations both display movement disorder with choreathetosis and dystonia as the most common pattern (Saitou et al., 2016; Feng et al., 2018). Interestingly, patients with the R209H mutation have somewhat more choreoathetosis compared to those with the G203R mutation, although they display similar frequencies of dystonia (Feng et al., 2018). Such differences in patient phenotype may relate to the differences in the animal models behavior. In looking at the behavior of the R209H model specifically, the striking hyperactivity of the male R209H mutant mice points to increased dopamine signaling in the striatum as a possible mechanism. Suppression of that hyperactivity with risperidone is consistent with that mechanism.

The two movement disorder-associated *GNAO1* mutations R209H and G203R also have different patterns in *in vitro* studies of cAMP regulation in HEK-293T cells (Feng et al., 2017). Interestingly, the $G\alpha_o$ R209H mutant supports normal cAMP regulation and is expressed at normal levels both in HEK cells (Feng et al., 2017) and in the brain (this study). In contrast the G203R mutant is expressed at lower levels both in HEK cells (Feng et al., 2017) and in the mouse brain (Feng, H. Unpublished doctoral dissertation). Despite lower expression, it signals more strongly (GOF) in the HEK cell assay.

We also present two new pieces of information that provide insights into the pathogenicity of the R209H mutant $G\alpha_o$ despite its normal function in the HEK cell cAMP assay. Using a fluorescent nucleotide exchange assay with pure R209H mutant $G\alpha_o$, we demonstrate that the rate of binding of the GTP analog is ~6.2x faster than that of WT. This is typical for many hyperactive G protein mutants since GDP release is the rate-limiting step for activation. Indeed, receptors enhance GDP release rates to

JPET # 262733

activate the G protein (Iiri et al., 1994; Leyme et al., 2014; Toyama et al., 2017). Constitutive activation of G_{α_o} by the R209H mutant could lead to enhanced signaling in the indirect pathway, D2 dopamine receptor neurons in striatum. The striatum is a site of substantial G_{α_o} expression and enhanced G_{α_o} signaling could contribute to the hyperactivity phenotype seen in our studies. More detailed mechanistic studies of striatal neurons will be needed to further elucidate the downstream signaling mechanisms protein (e.g. ion channels, synaptic vesicle release, or neurite outgrowth) engaged by the mutant G_o in these mice and in patients.

Effective treatments are a key goal as patients with the R209H mutation experience repeated hospitalizations (Ananth et al., 2016; Marecos et al., 2018; Schirinzi et al., 2018). Deep brain stimulation in the internal globus pallidus has proven effective in *GNAO1* patients in attenuating MD (Kulkarni et al., 2016; Sanem et al., 2016; Honey et al., 2018; Koy et al., 2018). However, that invasive treatment is reserved for refractory patients. Risperidone is one of the oral treatments that has proven to be beneficial, specifically in a patient with the R209H mutation (Ananth et al., 2016). Risperidone is an atypical neuroleptic, antagonizing D_2 and 5-HT receptors. G_{α_o} couples to myriad GPCRs including the dopamine D_2 receptor which is involved in movement control (Neve et al., 2004). In our study, risperidone was able to significantly decrease the hyperlocomotion seen in our *Gnao1^{+R209H}* mouse model. At both the 0.5 mg/kg and 2.0 mg/kg dose of risperidone, hyperactivity was attenuated in our R209H mouse model. However, this response was not selective for the *Gnao1^{+R209H}* mutant mice as the WT mice also displayed a significant decrease in locomotion. This outcome suggests that risperidone

JPET # 262733

treatment may be effective in repressing global movement, while not specifically targeting a *Gnao1* R209H mechanism.

The new mouse model described here should provide a valuable tool for future mechanistic studies of *GNAO1* encephalopathies. The fact that the mouse has very distinct behavioral changes from our previous *Gnao1* mutant mouse models (R209H and G184S), indicates that it is very important to consider the mutant allele as well as the mutant gene in considering genetic disorders and personalized therapies.

JPET # 262733

Acknowledgements

The authors thank Dr. Michelle Mazei-Robison for her advice on organizing the behavioral battery experiments on our mutant mouse models.

Authorship Contributions

Participated in research design: Larrivee, Feng, Shaw.

Conducted experiments: Larrivee, Feng, Quinn and Shaw.

Contributed to animal model development and maintenance: Leipprandt, Demireva, and Xie.

Performed data analysis: Larrivee, Feng, Shaw.

Wrote or contributed to the writing of the manuscript: Larrivee, Feng, Demireva and Neubig.

REFERENCES

- Ananth AL, Robichaux-Viehoever, Young-Min A, Young-Min K, Andrea H-K, Rachel C, M. EG, Jonathan S, Marcia W, L. SB, W. WY and A. BJ (2016) Clinical Course of Six Children With GNAO1 Mutations Causing a Severe and Distinctive Movement Disorder. *Pediatr Neurol* **59**:81-84.
- Arya R, Christine S, L. GD, L. LJ and D. HK (2017) GNAO1 -associated epileptic encephalopathy and movement disorders: c. 607G\textgreaterA variant represents a probable mutation hotspot with a distinct phenotype. *Epileptic Disord* **19**:67-75.
- Blumkin L, Tally L-S, Ana W, Hilla B-P, Ayelet Z, Keren Y and Dorit L (2018) Multiple Causes of Pediatric Early Onset Chorea-Clinical and Genetic Approach. *Neuropediatrics* **49**:246-255.
- Bruun TUJa (2018) Prospective cohort study for identification of underlying genetic causes in neonatal encephalopathy using whole-exome sequencing. *Genet Med* **20**:486-494.
- Carvalho RC, Silva RH, Abílio VC, Barbosa PN and Frussa-Filho R (2003) Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice. *Brain Res Bull* **60**:115-124.
- Consortium E-R, Project EPG and Consortium EK (2014) De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. *Am J Hum Genet* **95**:360-370.
- Consortium EK (2016) De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. *Am J Hum Genet* **99**:287-298.
- Danti FR, Serena G, Marta R, Martino M, J. CK, Lucy RF, Elena P and Claudia B (2017) GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome. *Neurol Genet* **3**:e143.
- Deacon RM, Nielsen S, Leung S, Rivas G, Cubitt T, Monds LA, Ezard N, Larance B and Lintzeris N (2016) Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling. *Int J Drug Policy* **36**:104-111.
- Dhamija R, W. MJ, B. SB and P. GH (2016) GNAO1 -Associated Movement Disorder. *Movement Disorder Clinical Practice* **3**:615-617.
- Dhir A (2012) Pentylentetrazol (PTZ) kindling model of epilepsy. *Curr Protoc Neurosci*

Chapter 9:Unit9.37.

Feng H, Khalil S, Neubig RR and Sidiropoulos C (2018) A mechanistic review on GNAO1-associated movement disorder. *Neurobiol Dis*.

Feng H, Larrivee CL, Demireva EY, Xie H, Leipprandt JR and Neubig RR (2019) Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes. *PLoS One* **14**:e0211066.

Feng H, Sjögren B, Karaj B, Shaw V, Gezer A and Neubig RR (2017) Movement disorder in. *Neurology* **89**:762-770.

Gawlinski P, Renata P, Tomasz G, Danuta S, Monika C, Beata N, N. JS, M. MD, Monika B-F, Eric BJaB, A. GR, R. LJ and Wojciech W (2016) PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies. *Pediatr Neurol* **60**:83-87.

Gerald B, Keri R, Newell B, Szabolcs S, L. SA, Chris B, Megan R, Ryan R, Matt DB, M. CA, Isabelle S, J. HM, W. CD, Sampathkumar R and Vinodh N (2018) Neonatal epileptic encephalopathy caused by de novo GNAO1 mutation misdiagnosed as atypical Rett syndrome: Cautions in interpretation of genomic test results. *Semin Pediatr Neurol* **26**:28-32.

Honey CM, K. MA, Maja T-G, M. vKCD, Gabriella H and Adi S (2018) GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation. *J Child Neurol* **33**:413-416.

Iiri T, Herzmark P, Nakamoto JM, van Dop C and Bourne HR (1994) Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. *Nature* **371**:164-168.

Kehrl J, Sahaya K, Dalton HM, Charbeneau RA, Kohut KT, Gilbert K, Pelz MC, Parent J and Neubig RR (2014) Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)? *Mamm Genome* **25**:202-210.

Koy A, Sebahattin C, Victoria G, Kerstin B, Thomas R, Christophe M, Julien B, Gilles C, Alain B, Frederic G, Pierre-Francois P, Claude C, Nathalie D, Diane D, Agathe R, Christophe B, Friederike K, Burkhard S, Stephan W, Cyril M, Caroline N, Mohammad M, Philippe C and Laura C (2018) Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia. *J Neurol Sci* **391**:31-39.

Kulkarni N, Tang S, Bhardwaj R, Bernes S and Grebe TA (2016) Progressive Movement Disorder in Brothers Carrying a GNAO1 Mutation Responsive to Deep Brain Stimulation. *J Child Neurol* **31**:211-214.

Law C-Y, Tzu-Lun CS, Young CS, Kin-Cheong YE, Sui-Fun NG, Nai-Chung F and Ching-Wan L (2015) Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy. *Clin Chim Acta* **451**:292-296.

Lee E, Linder ME and Gilman AG (1994) Expression of G-protein alpha subunits in *Escherichia coli*. *Methods Enzymol* **237**:146-164.

Leyme A, Marivin A, Casler J, Nguyen LT and Garcia-Marcos M (2014) Different biochemical properties explain why two equivalent G α subunit mutants cause unrelated diseases. *J Biol Chem* **289**:21818-21827.

Marcé-Grau A, James D, Javier L-P, Concepción G-JM, Lorena M-G, Ester C-L, Jesús G and Alfons M (2016) GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females. *Orphanet J Rare Dis* **11**:38.

Marecos C, Duarte S, Alonso I, Calado E, and Moreira A (2018) GNAO1 : a new gene to consider on early-onset childhood dystonia . *Rev Neurol* **66**:321-322.

McEwen DP, Gee KR, Kang HC and Neubig RR (2002) Fluorescence approaches to study G protein mechanisms. *Methods Enzymol* **344**:403-420.

Menke LA, Marc E, Mariel A, J. OVJ, Frank B and M. CJ (2016) Recurrent GNAO1 mutations associated with developmental delay and a movement disorder. *J Child Neurol* **31**:1598-1601.

Meredith K, Meredith P, Ivana M, Anne R, Marie G, Eduardo P-P, Takle AE, Y. HC, Lindsay OHaS, Irina A, C. BL, A. HF, A. SD, Network UD, Saima K, Molly S, Sophie C, E. SI, Edward Y, L. WJ, Dennis L, Olaf B and Annapurna P (2019) Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region. *Epilepsia*.

Nakamura K, Hirofumi K, Tenpei A, Masaaki S, Mitsuhiro K, Hideki H, Hiroshi T, Hitoshi O, Shinichi N, Jun T, Tatsuro K, Tomonori F, Satomi I, Takashi S, Masaya K, Satoko M, Eriko K, Kiyomi N, Mitsuko N, Yoshinori T, Noriko M, Kiyoshi H, Kazuhiro O, Atsuo F, Naomichi M and Hiroto S (2013) De Novo mutations in GNAO1 , encoding a G α subunit of heterotrimeric G proteins, cause epileptic encephalopathy. *Am J Hum Genet* **93**:496-505.

Neve KA, Seamans JK and Trantham-Davidson H (2004) Dopamine receptor signaling. *J Recept Signal Transduct Res* **24**:165-205.

Okumura A, Koichi M, Mami S, Hirokazu K, Atsushi I, Shingo N, Shinichi H, Tomoko K, Manami I, Shinsuke K, Yusuke O, Hideki M and Seiji K (2018) A patient with a GNAO1 mutation with decreased spontaneous movements, hypotonia, and dystonic features. *Brain Dev* **40**:926-930.

Rim JH, Hee KS, Sik HI, Sung KS, Jieun K, Woo KH, Jung CM, Ara K, Ee YS, Jihun K, Mock LY, Jung CH, Soo LJ, Dong KH, Rak CJ, Seung-Tae L and Hoon-Chul K (2018) Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing. *BMC Med Genomics* **11**:6.

Saitsu H, Ryoko F, Bruria B-Z, Yasunari S, Masakazu M, Nobuhiko O, Yasuhiro S, Yukifumi M, Hiroshi S, Barak T, Michiko T, Satoshi A, Nagahisa T, Hitoshi O, Takanori Y, Kazuyuki N, Yoshinori T, Mitsuko N, Noriko M, Masaaki S, Kazuhiro O and Naomichi M (2016) Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay. *Eur J Hum Genet* **24**:129-134.

Sakamoto S, Yukifumi M, Ryoko F, Noriko M, Hiroshi S, Akihiko M, Ayumi M, Masako N, Hitoshi O, Naomichi M and Takanori Y (2017) A case of severe movement disorder with GNAO1 mutation responsive to topiramate. *Brain Dev* **39**:439-443.

Sanem Y, Tuncer T, Serdar C, Sarenur G, Hasan T and Gul S (2016) Excellent response to deep brain stimulation in a young girl with GNAO1 -related progressive choreoathetosis. *Childs Nerv Syst* **32**:1567-1568.

Schirinzi T, Giacomo G, Lorena T, Gessica V, Serena G, Loreto R, Claudia C, Claudia B, Domenica B, Luigia GM, Laura C, Federica G, Efsio MC, Enrico C, Enrico B, Alessandro C and Vincenzo L (2018) Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. *Parkinsonism Relat Disord*.

Schorling DC, Tobias D, Christina E, Katrin H, Rudolf K, Daniel E, G. BC and Janbernd K (2017) Expanding phenotype of de novo mutations in GNAO1 : four new cases and review of literature. *Neuropediatrics* **48**:371-377.

Seibenhener ML and Wooten MC (2015) Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. *J Vis Exp*:e52434.

Takezawa Y, Atsuo K, Kazuhiro H, Tetsuya N, Yurika N-U, Takehiko I, Saeko Y-S, Takuya M, Mai A, Sato S-M, Yukimune O, Wakaba E, Noriko T, Yasuko K, Akira O, Ryo F, Matsuyuki S, Keiko N, Yoko A and Shigeo K (2018) Genomic analysis identifies masqueraders of full-term cerebral palsy. *Ann Clin Transl Neurol* **5**:538-551.

Talvik I, S. MoR, Merilin V, Ulvi V, Hg LL, A. DH, Pilvi I and Tiina T (2015) Clinical phenotype of de novo GNAO1 mutation: case report and review of literature. *Child Neurology Open* **2**:2329048X15583717.

Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H and Nagaraju K (2014) Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. *J Vis Exp*:51785.

JPET # 262733

Toyama Y, Kano H, Mase Y, Yokogawa M, Osawa M and Shimada I (2017) Dynamic regulation of GDP binding to G proteins revealed by magnetic field-dependent NMR relaxation analyses. *Nat Commun* **8**:14523.

Waak M, S. MS, David C, Kate S, Lisa C, Peter S and Terry C (2018) GNAO1 -related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS . *J Neurol Neurosurg Psychiatr* **89**:221-222.

Xiong J, Jing P, Hao-Lin D, Chen C, Xiao-Le W, Shi-Meng C and Fei Y (2018) Recurrent convulsion and pulmonary infection complicated by psychomotor retardation in an infant . *Zhongguo Dang Dai Er Ke Za Zhi* **20**:154-157.

JPET # 262733

Footnotes

Funding

This work was supported by a grant from the Bow Foundation [2];

Michigan State University's department of Comparative Medicine and Integrative Biology, and the MSU discretionary funding initiative [34149].

No financial disclosures

Legends for Figures

Figure 1. Targeting of the mouse *Gnao1* locus (A) Mouse *Gnao1* genomic locus (exon size not to scale), red outline is magnified in (B) showing exon 6 and relative location of codon 209 and PCR primers O586 and O587. (C) Location and exact sequence of gRNA target within exon 6, dotted red line denotes DSB, PAM is highlighted and sequence corresponding to gRNA protospacer is underlined (also in E). (D) Raw gel electrophoresis images showing PCR of the target region and T7 Endonuclease I (T7 Endo I) digestion analysis of founders 1324 – 1335 (n=12), with WT, H2O (-) and T7Endo I (+) controls. Founder 1324 (red number) was positive for the mutation on one allele and WT on the other, note that the single bp mismatch was not reliably detected by T7 Endo I assay. (E) Exact sequence of edited founder 1324 as aligned to WT reference genome, two peaks (G and A) are detected on the sequence chromatogram, indicating the presence of both WT and edited R209H allele.

Figure 2. *Gnao1*^{+/R209H} mice show significant hyperactivity and reduced time in center in the open field arena (A) Representative heat maps of *Gnao1*^{+/R209H} mice and *Gnao1*^{+/+} mice in the open field arena (B) Time spent in the open field arena was separated into 0-10 minutes (novelty) and 10-30 minutes (sustained). *Gnao1*^{+/R209H} male and female mice exhibit increased locomotion in the novelty period. Hyperactivity observed in the sustained period and for total travel time (2- way ANOVA; ****p < 0.0001, ***p < 0.001, * p < 0.05). Female R209H mutant mice also showed significantly greater distance traveled in the novelty period (*, P<0.05). *Gnao1*^{+/R209H} mice of both sexes spend less time in center areas of the open field arena compared to wildtype littermates. (C) Neither male nor female *Gnao1*^{+/R209H} mice show significant differences on the rotarod. (D) There is also no significant difference in grip strength between wildtype and *Gnao1*^{+/R209H} mice. Data are shown as mean ± SEM.

Figure 3. Male and female *Gnao1*^{+/R209H} mice shows gait abnormalities in different tests on the DigiGait imaging system (A & B) Male *Gnao1*^{+/R209H} mice showed reduced stride length compared to wildtype littermates (2-way ANOVA with Bonferroni multiple comparison post-test), while female *Gnao1*^{+/R209H} mice showed a normal stride length. (C & D) Neither male nor female *Gnao1*^{+/R209H} exhibited significant differences in paw angle variability compared to wildtype littermates. (E) At speeds greater than 25 cm/s female *Gnao1*^{+/R209H} had a reduced ability to run on the treadmill

Figure 4. *Gnao1*^{+/R209H} mice do not have an enhanced pentylenetetrazol (PTZ) kindling response (A&B) Neither male nor female *Gnao1*^{+/R209H} mice showed significant differences in sensitivity to PTZ injection compared to wildtype littermates (n.s. Mantel-Cox test)

JPET # 262733

Figure 5. Biochemical analysis of brain $G\alpha_o$ protein levels and *in vitro* nucleotide exchange for WT and R209H mutant $G\alpha_o$. A) Brain regions (cortex, hippocampus, striatum, cerebellum, brain stem and olfactory bulb homogenates) from WT and *Gnao1*^{+/R209H} mice were assessed by Western blot for levels of $G\alpha_o$ protein. B) Protein levels of *Gnao1*^{+/R209H} brain samples were quantified using Li-Cor IRDye staining and values were normalized to actin levels and then to the control sample from WT run on the same day. There was no significant difference in any of the regions between WT and mutant mice (n=7). C & D) The kinetics of BODIPY-FL GTP γ S binding were measured as described in Materials and Methods. The time course of the fluorescence increase was fit to an exponential function (connecting lines) and the T1/2 calculated from the rate constant of the exponential function (see methods). Nucleotide binding experiments were performed in duplicate and results from the separate days were averaged. Error bars and mean \pm SD (n=3). For some data points, error bars are smaller than the symbol and are not shown.

Figure 6. Risperidone treatments decreases hyperkinetic movements in *Gnao1*^{+/R209H}

(A) *Gnao1*^{+/R209H} mice show complete abrogation of movement compared to vehicle treated *Gnao1*^{+/R209H} littermates following a 2.0 mg/kg dose of risperidone. Student's unpaired *t*-test (B) At 0.5 mg/kg both WT and *Gnao1*^{+/R209H} exhibit a significant decrease in locomotion compared to vehicle controls. Student's unpaired *t*-test. Wildtype mice also show a decrease in locomotion after 0.5 mg/kg risperidone treatment. (C) Comparison of 2.0 mg/kg and 0.5 mg/kg treatment in WT and *Gnao1*^{+/R209H} mice. Hyperactivity of *Gnao1*^{+/R209H} mice was observed during baseline testing and recovered following the 2-day risperidone washout.

JPET # 262733


Tables

Table 1. Location and sequence of gRNA and ssODN template for CRISPR-Cas targeting *Gnao1* locus; primers and genotyping method for *Gnao1*^{+/R209H} mice.


	<i>Gnao1</i> R209H
Location	Chr 8: 93,950,334
gRNA target 5' N20-PAM -3'	5' AGCGATCTGAACGCAAGAAG TGG 3'
ssODN template (reverse complement)	GTTTCGTCCTCGTGGAGCACCTGGTCA TAGCCGCTGAGTGCACACAGAAGATGATGGC CGTGACATCCTCAAAGCAGTGGATCCACTTCTT GtGTTTCAGATCGCTGGCCCCGACGTCAAACAG CCTGCAGGGAGTCAGGGAAAGCTGTGAGGGC GGGGACGCCTA
PCR primers	O586 FWD: 5' GGACAGGTGTCACAGGGGAT 3' O587 REV: 5' ACTGGCCTCCCTTGGCAATA 3'
Genotyping	By Sanger Sequencing

Figures


1





2




3



4





6

